|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Privately Held (Funded) |
Company Size: |
0-9 Employees In BC (10-19 Total)
0-9 In BC (10-19 Total)
|
Year Founded: |
2012 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
Phoenix Molecular Designs, PhoenixMD, biotechnology
|
|
|
|
Phoenix Molecular designs is a biotechnology company that is developing game changing small molecule kinase inhibitors as a targeted therapy for Cancer. We are focused on treating one of the most aggressive types of breast cancer, Triple Negative Breast Cancer (TNBC), which currently does not have any approved targeted treatments.
Our innovative treatment potently inhibits cancer cells and is less toxic than the current standard of care.
Our patented cancer compounds position us in the lead to fast track our product to market as it fills an unmet medical need as an effective, safer treatment for a serious medical condition. Our cancer therapy will potentially save lives and improve the lives of cancer patients. Please visit our website at www.phoenixmd.ca for more information. |
|
|
Date |
Type |
Amount |
Investors |
Nov 26, 2019 |
Seed |
$12 Million CAD |
Investors in the financing round included Pallasite Ventures and World Changing Ventures. |
Date |
Type |
Amount |
Investors |
Nov 26, 2019 |
Seed |
$12M CAD |
Investors in the financing round included Pallasite Ventures and World Changing Ventures. |
|
|
|
Want More Phoenix Molecular Designs News? 1
|
Next »
|
|
|
|
|
|
|
Nov 29, 2019
|
Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer
|
|
Nov 27, 2019
|
Vancouver-based Phoenix Molecular Designs Announces $12 Million in Seed Financing
|
|
Oct 9, 2019
|
Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a First-in-Class RSK Inhibi
|
|
Jul 25, 2019
|
Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC
|
|
Mar 28, 2019
|
Phoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directors
|
|
Jan 28, 2019
|
Vancouver-based Biotech Company Phoenix Molecular Designs Announces Collaboration with Pharma Giant Roche
|
|
Sep 24, 2018
|
Phoenix Molecular Designs Raises $2.7 Million Financing Led by Pallasite Ventures
|
|
May 1, 2018
|
Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND
|
|
Jul 21, 2017
|
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
|
|
|
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
